Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world phase 4 study of mulberry branch total alkaloid tablets in type 2 diabetes mellitus
ChiCTR2500095995Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ramulus mori alkaloids in type 2 diabetes mellitus (T2DM), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoints: HbA1c at 24 weeks and 1-hour postprandial venous blood glucose at 24 weeks. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
ramulus mori alkaloids
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500095995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095995.